 MASS (£7600/life-year gained) suggest
that AAA screening in England and other European
countries will remain cost-effective even with prevalence
rates as low as 1%.260-262
Other challenges to efﬁcient implementation of
screening include the identiﬁcation and exclusion of patients who have had prior abdominal cross-sectional imaging studies, accounting for increasing longevity,
potential needs for late rescreening,263 and selective
screening to optimize